PBYI Quote, Financials, Valuation and Earnings

Nephros, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of 7.07%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Nephros, Inc.'s return on equity of 16.22%.

Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -40.78%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 39.49%. Given that Nephros, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Nephros, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.177, which suggesting that the stock is 17.656% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.483, suggesting its more volatile than the S&P 500 by 48.288%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Nephros, Inc.'s net income of $337K. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 7.98x while Nephros, Inc.'s PE ratio is 33.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.40x versus 2.80x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sensus Healthcare, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of -13.7%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Sensus Healthcare, Inc.'s return on equity of -5.65%.

Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -40.78%. On the other hand Sensus Healthcare, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 93.49%. Given that Sensus Healthcare, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Sensus Healthcare, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.177, which suggesting that the stock is 17.656% more volatile than S&P 500. In comparison Sensus Healthcare, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.559%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensus Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Sensus Healthcare, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are larger than Sensus Healthcare, Inc. quarterly revenues of $6.9M. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Sensus Healthcare, Inc.'s net income of -$943K. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 7.98x while Sensus Healthcare, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.40x versus 1.74x for Sensus Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of -40.15%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -40.78%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 71.78%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.177, which suggesting that the stock is 17.656% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 7.98x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.40x versus 1.89x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of 34.76%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -40.78%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $489.04 which suggests that it could grow by 6.5%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.177, which suggesting that the stock is 17.656% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Puma Biotechnology, Inc.'s net income of $8.8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 7.98x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.40x versus 10.14x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.